Literature DB >> 17897854

Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation.

Julien Becker1, Carine Delayre-Orthez, Nelly Frossard, Françoise Pons.   

Abstract

Peroxisome proliferator-activated receptor-alpha (PPARalpha) is implicated in the control of airway inflammation. However, little is known so far about PPARalpha expression and regulation in the lung. Our aim was to assess PPARalpha expression in the lung from normal mice, as well as to investigate its regulation during airway inflammation or in response to anti-inflammatory agents. The PPARalpha activator, fenofibrate, the glucocorticoid, dexamethasone or vehicle was administered to normal mice, to mice exposed to tumor necrosis factor-alpha (TNF-alpha) or lipopolysaccharide (LPS) or to ovalbumin (OVA)-sensitized and challenged animals. PPARalpha expression was assessed by quantifying PPARalpha mRNA levels using real-time quantitative PCR after reverse-transcription of total lung RNA. Airway inflammation was evaluated by determining total and differential cell counts, as well as TNF-alpha production in bronchoalveolar lavage fluids. PPARalpha mRNA was found at significant levels in the lung from normal mice. This expression was increased by 65% (p<0.05) and 55% (p<0.05) in animals treated with fenofibrate and dexamethasone, respectively. In mice exposed to TNF-alpha or LPS, as well as in animals sensitized and challenged with OVA, that exhibited airway inflammation, PPARalpha mRNA was decreased by 60% (p<0.05), 43% (p<0.05) and 50% (p<0.05), respectively. In mice exposed to LPS, down-regulation of PPARalpha was maximal at 4h, whereas TNF-alpha production and cell infiltration peaked at 2 and 24h, respectively. In the lung of mice exposed to LPS or OVA and treated with fenofibrate or dexamethasone, PPARalpha down-regulation was suppressed, while airway inflammation was abolished. Our data showed that PPARalpha is constitutively expressed in mouse lung and down-regulated in response to TNF-alpha or upon acute or allergic airway inflammation. Fenofibrate and dexamethasone upregulated PPARalpha in normal lung and suppressed PPARalpha down-regulation associated with airway inflammation. Taken together, our data show that PPARalpha expression is inversely regulated with lung inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897854     DOI: 10.1016/j.pupt.2007.08.001

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  8 in total

1.  Modulation of the IL-23/IL-17 axis by fenofibrate ameliorates the ovalbumin/lipopolysaccharide-induced airway inflammation and bronchial asthma in rats.

Authors:  Samah M Elaidy; Soha S Essawy; Mona A Hussain; Mohamed K El-Kherbetawy; Eman R Hamed
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-30       Impact factor: 3.000

2.  Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6.

Authors:  Elizabeth J Hennessy; Frederick J Sheedy; David Santamaria; Mariano Barbacid; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

3.  PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure.

Authors:  Barbara Rinaldi; Maria Donniacuo; Emanuela Esposito; Annalisa Capuano; Loredana Sodano; Emanuela Mazzon; Donatella Di Palma; Irene Paterniti; Salvatore Cuzzocrea; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

4.  Inhibition of pulmonary β-carotene 15, 15'-oxygenase expression by glucocorticoid involves PPARα.

Authors:  Xiaoming Gong; Raju Marisiddaiah; Lewis P Rubin
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240

Review 5.  The Role of PPAR Alpha in the Modulation of Innate Immunity.

Authors:  Maja Grabacka; Małgorzata Pierzchalska; Przemysław M Płonka; Piotr Pierzchalski
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 5.923

6.  Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.

Authors:  Spencer Richman; Cole Lyman; Matthew Morris; Gordon Broderick; Anastasia Nesterova; Anton Yuryev; Hongbao Cao; Chris Cheadle; Gary Skuse
Journal:  NPJ Syst Biol Appl       Date:  2022-10-10

7.  Macrophages, PPARs, and Cancer.

Authors:  Jo A Van Ginderachter; Kiavash Movahedi; Jan Van den Bossche; Patrick De Baetselier
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

8.  PPARs in Irradiation-Induced Gastrointestinal Toxicity.

Authors:  Christine Linard; Maâmar Souidi
Journal:  PPAR Res       Date:  2009-11-22       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.